Journal of the American College of Cardiology
-
J. Am. Coll. Cardiol. · Oct 2012
Comparative StudyMultimarker strategy for short-term risk assessment in patients with dyspnea in the emergency department: the MARKED (Multi mARKer Emergency Dyspnea)-risk score.
The study aim was to determine the prognostic value of a multimarker strategy for risk-assessment in patients presenting to the emergency department (ED) with dyspnea. ⋯ A multimarker strategy provided superior risk stratification beyond any single-marker approach. The MARKED-risk score that incorporates hs-cTnT, hs-CRP, and Cys-C along with clinical risk factors accurately identifies patients with very low, intermediate, and high risk.
-
J. Am. Coll. Cardiol. · Oct 2012
Multicenter Study Comparative StudyPrediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death.
The aim of this study was to derive and validate a practical risk model to predict death within 4 years of primary prevention implantable cardioverter-defibrillator (ICD) implantation. ⋯ This useful model, based on more than 45,000 primary prevention ICD patients, accurately identifies patients at highest risk for death after device implantation and may significantly influence clinical decision making.
-
J. Am. Coll. Cardiol. · Oct 2012
Comparative StudyAdolescence risk factors are predictive of coronary artery calcification at middle age: the cardiovascular risk in young Finns study.
The purpose of this study was to examine the roles of adolescence risk factors in predicting coronary artery calcium (CAC). ⋯ Elevated adolescence LDL-C and systolic BP levels are independent predictors of adulthood CAC, indicating that adolescence risk factor levels play an important role in the pathogenesis of coronary heart disease.
-
J. Am. Coll. Cardiol. · Oct 2012
Randomized Controlled Trial Multicenter Study Comparative StudyA new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
The goal of this study was to evaluate shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation. ⋯ E-ZES+3-month DAPT was noninferior to the standard therapy with respect to the occurrence of the primary endpoint. (REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following E-ZES implantation [RESET]; NCT01145079).